Market Research

Heart Failure: Seven-Market Drug Forecast and Market Analysis - Update

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 137 Pages GlobalData November, 2024 GBDT19388740
Best Price Guarantee
Price from $10,995
Length 137 Pages
Publisher GlobalData
Published Date November, 2024
SKU GBDT19388740

Heart Failure: Seven-Market Drug Forecast and Market Analysis - Update



Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the heart failure market through 2032.

GlobalData estimates sales of HF therapeutics to be approximately $13.5 billion across the 7MM in 2022. By 2032, GlobalData expects the HF market to grow at a strong compound annual growth rate (CAGR) of 9.6%, reaching sales of $33.7 billion by the end of the forecast period.

Major drivers of HF market growth over the forecast period are the -
  • Anticipated expanded indication for Bayer’s Kerendia (finerenone)
  • Launch of several oral and injectable agents
  • Increase in the global prevalence of chronic HF
Major barriers that will restrict the growth of the HF market during the forecast period are the -
  • High price of recently developed HF therapies
  • General reluctance of cardiologists and other physicians to adopt and prescribe new HF therapies
  • Widespread use of generic HF drugs, making it difficult for high-priced branded therapies to penetrate the market
Scope
  • Overview of heart failure, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized heart failure therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the heart failure therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for heart failure treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global heart failure therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM heart failure therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM heart failure therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please note:this is delivered as a zip file.


About GlobalData
1 Heart Failure: Executive Summary - Updated October 2024, Based on Events up to October 24, 2024
1.1 The HF market will exhibit strong growth between 2022 and 2032
1.2 Label expansions of CV drugs will fuel market growth
1.3 Unmet needs remain in the HF market despite the availability of well-established therapies
1.4 Injectable agents will dominate the HF market
1.5 What do physicians think?
2 Introduction - Updated October 2024, Based on Events up to October 24, 2024
2.1 Catalyst
2.2 Related reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/targets of interest
3.2 Classification or staging systems
3.3 Prognosis
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction
4.4.5 Forecast assumptions and methods: hospitalizations for acute HF
4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations
4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction
4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes
4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction ≥50%) by New York Heart Association class
4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40-49%) by New York Heart Association class
4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction<40%) by New York Heart Association class
4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
4.5 Epidemiological forecast for HF (2022-32)
4.5.1 Diagnosed incident cases of HF
4.5.2 Age-specific diagnosed incident cases of HF
4.5.3 Sex-specific diagnosed incident cases of HF
4.5.4 Diagnosed incident cases of HF by ejection fraction
4.5.5 Hospitalizations for acute HF
4.5.6 Acute HF hospitalizations based on presentation
4.5.7 Hospital length of stay for acute HF
4.5.8 Re-admissions within 30 days post-discharge after acute HF
4.5.9 Diagnosed prevalent cases of HF
4.5.10 Age-specific diagnosed prevalent cases of HF
4.5.11 Sex-specific diagnosed prevalent cases of HF
4.5.12 Diagnosed prevalent cases of HF by ejection fraction
4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class
4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction ≥50%) by New York Heart Association class
4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40-49%) by New York Heart Association class
4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction<40%) by New York Heart Association class
4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management - Updated October 2024, Based on Events up to October 24, 2024
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Current Treatment Options - Updated October 2024, Based on Events up to October 24, 2024
6.1 Overview
7 Unmet Needs and Opportunity Assessment - Updated October 2024, Based on Events up to October 24, 2024
7.1 Overview
7.2 Lack of therapies for HF with preserved ejection fraction patients
7.3 Lack of therapies for acute HF
7.4 Compliance and optimal management of HF treatments
7.5 Preventative therapies for patients at risk of developing HF
8 R&D Strategies - Updated October 2024, Based on Events up to October 24, 2024
8.1 Overview
8.1.1 Label expansion for therapies approved for other indications
8.1.2 Mergers and acquisitions to expand the product pipeline
8.2 Clinical trials design
8.2.1 Clinical endpoints for HF
8.2.2 Inclusion and exclusion criteria
9 Pipeline Assessment - Updated October 2024, Based on Events up to October 24, 2024
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis - Updated October 2024, Based on Events up to October 24, 2024
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players - Updated October 2024, Based on Events up to October 24, 2024
11.1 Overview
11.2 Deal-making trends
12 Market Outlook - Updated October 2024, Based on Events up to October 24, 2024
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Vice President of Disease Intelligence and Epidemiology
13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
Contact Us
List of Tables
Table 1: Heart failure: key metrics in the 7MM
Table 2: Types of chronic HF
Table 3: Causes of HF
Table 4: Compensatory mechanisms in HF patients
Table 5: Symptoms of HF
Table 6: Types of chronic HF
Table 7: Comparison of two HF classification systems
Table 8: Risk factors and comorbidities for HF
Table 9: Treatment guidelines for HF
Table 10: Top 10 deals by value, 2019-24
Table 11: HF market - global drivers and barriers, 2022-32
Table 12: Key events impacting sales for HF in the US, 2022-32
Table 13: HF market - drivers and barriers in the US, 2022-32
Table 14: Key events impacting sales for HF in the 5EU, 2022-32
Table 15: HF market - drivers and barriers in the 5EU, 2022-32
Table 16: Key events impacting sales for HF in Japan, 2022-32
Table 17: HF market - drivers and barriers in Japan, 2022-32
Table 18: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for HF in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in HF during the forecast period
Figure 3: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
Figure 4: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
Figure 5: Changes in cardiac structure in HF
Figure 6: 7MM, diagnosed incidence of HF (cases per 100,000 population), men and women, all ages, 2022
Figure 7: 7MM, diagnosed prevalence of HF (%), men and women, all ages, 2022
Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of HF
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of HF by EF
Figure 10: 7MM, sources used to forecast the hospitalization for acute HF
Figure 11: 7MM, sources used to forecast the hospitalizations for acute HF by presentation
Figure 12: 7MM, sources used to forecast the hospital LoS for acute HF
Figure 13: 7MM, sources used to forecast the re-admissions within 30 days post-discharge after acute HF hospitalization
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of HF
Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by NYHA class
Figure 17: 7MM, sources used to forecast the diagnosed prevalent cases of HF-PEF, HF-mrEF, and HF-REF by NYHA class
Figure 18: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 19: 7MM, diagnosed incident cases of HF, N, both sexes, all ages, 2022
Figure 20: 7MM, diagnosed incident cases of HF by age, N, both sexes, 2022
Figure 21: 7MM, diagnosed incident cases of HF by sex, N, all ages, 2022
Figure 22: 7MM, diagnosed incident cases of HF by EF, N, both sexes, all ages, 2022
Figure 23: 7MM, hospitalizations for acute HF, N, both sexes, all ages, 2022
Figure 24: 7MM, acute HF hospitalizations based on presentation, N, both sexes, all ages, 2022
Figure 25: 7MM, hospital LoS for acute HF, days, both sexes, all ages, 2022
Figure 26: 7MM, re-admissions within 30 days post-discharge after acute HF hospitalization, N, both sexes, all ages, 2022
Figure 27: 7MM, diagnosed prevalent cases of HF, N, both sexes, all ages, 2022
Figure 28: 7MM, diagnosed prevalent cases of HF by age, N, both sexes, 2022
Figure 29: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 30: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 31: 7MM, diagnosed prevalent cases of HF by NYHA classes, N, both sexes, all ages, 2022
Figure 32: 7MM, diagnosed prevalent cases of HF-PEF (LVEF ≥50%) by NYHA class, N, both sexes, all ages, 2022
Figure 33: 7MM, diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class, N, both sexes, all ages, 2022
Figure 34: 7MM, diagnosed prevalent cases of HF-REF (LVEF<40%) by NYHA class, N, both sexes, all ages, 2022
Figure 35: 7MM, diagnosed prevalent cases of HF by ACCF/AHA stages, N, both sexes, all ages, 2022
Figure 36: Diagnosis algorithm for chronic HF
Figure 37: Unmet needs and opportunities in chronic and acute HF
Figure 38: Overview of the development pipeline in HF
Figure 39: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for HF in the 7MM during the forecast period
Figure 40: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
Figure 41: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care (SOC)
Figure 42: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care (SOC)
Figure 43: Analysis of the company portfolio gap in HF during the forecast period
Figure 44: Global (7MM) sales forecast by country for HF in 2022 and 2032
Figure 45: Sales forecast by class for HF in the US in 2022 and 2032
Figure 46: Sales forecast by class for HF in the 5EU in 2022 and 2032
Figure 47: Sales forecast by class for HF in Japan in 2022 and 2032

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings